HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Benjamin Medalion Milton Saute Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ollech, J. E. Articles by Shitrit, D. Search for Related Content PubMed PubMed Citation Articles by Ollech, J. E. Articles by Shitrit, D. Related Collections Lung - cancer Lung - other Lung - basic science

Post-transplant diabetes mellitus in lung transplant recipients: incidence and risk factors

^a Pulmonary Institute, Rabin Medical Center, Beilinson Campus (affiliated with Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel), Petah Tiqwa 49100, Israel
^b Cardiothoracic Surgery Department, Rabin Medical Center, Beilinson Campus (affiliated with Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel), Petah Tiqwa 49100, Israel

Received 8 October 2007; received in revised form 24 December 2007; accepted 8 January 2008.

^_* Corresponding author. Tel.: +972 3 9377221; fax: +972 3 9377142. (Email: davids3{at}clalit.org.il).

Objective: Post-transplant diabetes mellitus (PTDM) is a common and potentially serious complication after solid organ transplantation. There are only a few data, however, about the incidence of DM in patients undergoing lung transplantation. Patients and methods: The medical records of 119 consecutive patients who underwent lung transplantation from 1998 to September 2004 were reviewed. Patients were divided in three groups according to their diabetes status, including pre-transplant DM, the PTDM group and those without DM. Patient records and all laboratory data were reviewed and the clinical course of diabetes was monitored. All recipients were treated with tacrolimus based regimen. Results: Mean follow-up for all patients was 25 ± 10. Twenty-three patients had DM in the pre-lung transplantation (LTX) DM group. PTDM developed in 34 of the remaining 96 patients (35.4%) with an incidence of 20%, 23% after 6 months and 12 months post-transplant. No significant difference was noted between 12 and 24 months post-LTX. The patients who developed DM were older (57 ± 15 vs 53 ± 13 years, p = 0.009), had increased BMI (26 ± 5 vs 24 ± 4, p = 0.0001), shorter time from diagnosis to LTX (21 ± 13 vs 28 ± 18 months, p = 0.007) more cytomegalovirus infection and more acute rejection and hyperglycemia in the first month after LTX. Four patients died in the PTDM group compared to nine patients in the no-DM group (12% vs 14%; p = 0.72). Conclusions: Post-transplant diabetes is a common complication in lung transplant patients receiving tacrolimus-based immunosuppression. The risk for developing PTDM is greatest among older recipients, those obese, and among recipients with more rejections episodes.

Key Words: Lung transplantation • Diabetes • Rejection • Tacrolimus

This article has been cited by other articles:

				D. M. Lyu and M. R. Zamora Medical Complications of Lung Transplantation Proceedings of the ATS, January 15, 2009; 6(1): 101 - 107. [Abstract] [Full Text] [PDF]